Montreal-based TOPIGEN Pharmaceuticals Inc has secured $26 million in series C financing to accelerate Phase II clinical programs related to its lead products for respiratory therapeutics. The total raised to date from all sources is now $75 million and more may be added to the C series. Investors in the latest round are NovaQuest, MMV Financial Inc, BDC Venture Capital, Desjardins Venture Capital, Caisse de Depot et Placement du Quebec, T2C2/BIO 2000 and Lothian Partners 27. TOPIGEN therapeutics suppress pulmonary inflammation by delivering drugs directly to the site of cellular action in the lung through inhalation. Its two lead products target asthma and chronic obstructive pulmonary disease….
Other stories mentioning these organizations, people and topics
| Organizations: | BDC Venture Capital, Caisse de dépot et placement du Québec, Desjardins Venture Capital, Lothian Partners 27, MMV Financial Inc, NovaQuest, and TOPIGEN Pharmaceuticals |
Other News
Events For Leaders in
Science, Tech, Innovation, and Policy
Discuss and learn from those in the know at our virtual and in-person events.
See Upcoming Events
You have 1 free article remaining.
Don't miss out - start your free trial today.
Start your FREE trial Already a member? Log in
By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.